| abstract |
The present invention relates to a use of a fusion protein comprising fibroblast growth factor receptor 2 (FGFR2) as a cancer diagnosis marker and/or a treatment target, and provides a fusion protein comprising the FGFR2, a composition for diagnosing cancer comprising a material that interacts with the fusion protein, a method for providing information for cancer diagnosis by using same, a composition for preventing and/or treating cancer comprising an inhibitor of the fusion protein, and a method for screening a cancer treatment agent using the fusion protein. |